A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Inclusion Criteria:

• Participants must have signed and dated an Institutional Review Board/ IndependentEthics Committee (IRB/IEC)-approved written informed consent form (ICF) inaccordance with regulatory, local, and institutional guidelines

• Participants must be ≥16 years of age at the time of signing the ICF

• Meet the European League Against Rheumatism (EULAR) / American College ofRheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus (SLE)

• Have an inadequate response to glucocorticoids and ≥ 2 immunosuppressant therapies,one of which is a biologic therapy consistent with treatment guidelines, used for atleast 3 months each. Eligibility is regardless of prior hydroxychloroquine or anyanti-malarial treatment. Inadequate response is defined as a lack of response,insufficient response, or lack of sustained response after at least 3-monthtreatment with appropriate doses of a standard of care agent. Intolerance orcontraindication may be considered as inadequate response provided it is documentedand confirmed acceptable by the Adjudication Committee

• Have active disease at study entry when signing ICF, defined as:

• ≥ 1 British Isles Lupus Assessment Group Index (BILAG) A OR ≥ 1 BILAG B withhistory of SLE manifestations that would qualify for a BILAG A within the last 24 months, AND

• Positive autoantibodies (at least one) to confirm diagnosis of SLE: Antinuclearantibody ≥1:160, anti-dsDNA, anti-Sm, anti-Ro (SSA), anti-La (SSB), or lowcomplement proteins (C3 or C4)

• Participants with lupus nephritis (LN) meeting the study eligibility criteria musthave had a renal biopsy per standard of care within 6 months (± 30 days) prior tosigning the ICF, indicating the presence of active Class III or IV LN (alone or incombination with Class V) according to the 2018 Revised International Society ofNephrology/Renal Pathology Society (ISN/RPS), with < 60% interstitial fibrosis andtubular atrophy < 60% global glomerulosclerosis

Exclusion Criteria:

• Pregnant women

• Participants enrolled in concurrent interventional clinical trials involvinginvestigational therapies or any other clinical trial

• Participant is unwilling or unable to comply with routine clinical follow-upnecessary for collection of study data